TP53 and cancer: ACESOT-1051 is still an ongoing first-in-human Phase 1 study, with a special focus on cancer-associated gene alterations, such as overexpression of CCNE1/2, loss-of-function mutation in FBXW7, PPP2R1A, or KRAS GLY12 or GLY13 with TP53 co-mutation [146].